. 2017 May 9;19(11):1481–1493. doi: 10.1093/neuonc/nox052

Table 1.

Synthetically lethal genes in the siRNA screens in SUM149 and MDA-MB-231Br TNBC cells with PI3K or MEK inhibition*

Drug	Selumetinib			Buparlisib
Cell Line	SUM149	MDA-MB-231Br	Combined	SUM149	MDA-MB-231Br	Combined
Dose (IC ₂₅)	200 nM	5.04 µM	N/A	810 nM	850 nM	N/A
Gene “Hits”	*BRAF, RAF1 (CRAF), MAP4K3, MAP2K1 (MEK1), MAP2K5, MAPK10, MAPK11* *PIK3C2A,* *PIK3C3, PIK3CB, PIK3R4* *PDGFRB* CDK2, CDK3, CDK5, CDK6, AURKB, BUB1B EPHA1, EPHA3, EPHA4, EPHA6, EPHB1, EPHB3, EPHB4, EFNB3 INSR, FLT1 (VEGFR1), FGFR4, ERBB4, TGFBR2	*BRAF, RAF1 (CRAF), MAP4K1, MAP4K3, MAP3K5, MAP3K7,* *MAP3K12, MAP2K2 (MEK2), MAP2K7, MAPK1 (ERK2), MAPK4 (ERK4), MAPK7, MAPK10, RPS6KA2 (RSK3), RPS6KA4 (MSK2), RPS6KA5 (MSK1) PIK3C2B, AKT2, RPS6KB1 (S6K1) PDGFRB* CDK2, CDK3, CDK4, CDK5, CDK5R1, CDK7, CDK9, CDK11, CHEK2 EPHA1, EPHA3, EPHA4, EPHA10, EPHB1, EPHB3, EPHB4 INSR, EGFR, FLT1 (VEGFR3), TGFBR2	*BRAF, RAF1 (CRAF), MAP4K1, MAP4K3, MAP3K1, MAP3K3, MAP3K5, MAP3K6, MAP3K7, MAP3K10, MAP3K12,* *MAP2K1 (MEK1),* *MAP2K2 (MEK2),* *MAP2K4, MAP2K5,* *MAP2K6, MAP2K7, MAPK1 (ERK2),* *MAPK10, MAPK11,* *RPS6KA1 (RSK1),* *RPS6KA5 (MSK1), DUSP21* *PIK3CB, PIK3C2B, PIK3C3, PIK3CD, PIK3R4* *PDGFRA, PDGFRB* CDK2, CDK3, CDK5, CDK5R1, CDK6, CDK9, CDK11, AURKB, PLK3, DDR1, CHEK2 EPHA1, EPHA3, EPHA4, EPHA6, EPHB1, EPHB3, EPHB4 INSR, INSRR, FLT1 (VEGFR1), FGFR4, TGFBR2	*MAP2K1 (MEK1) AURKA, BUB1*	*BRAF, RAF1 (CRAF), TAO1 (TAOK1),* *MAP4K3, MAP3K5,* *MAP3K13, MAP3K14, MAP2K7, MAPK6 (ERK3), RPS6KA1 (RSK1), RPS6KA3 (RSK2) AKT2, RPS6KB1 (S6K1) AURKC, BUB1, BUB1B,* PLK3, DDR2 EPHB3 TGFBR1	*BRAF, RAF1 (CRAF), TAO1 (TAOK1), MAP4K3, MAP3K5,* *MAP3K14, MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K5, MAP2K7, MAPK1 (ERK2), MAPK10, RPS6KA1 (RSK1),* *RPS6KA3 (RSK2),* *RPS6KA4 (MSK2), DUSP21* PIK3CB, AKT2 AURKA, AURKC, BUB1, BUB1B, DDR2 EFNA3, EFNA5, EFNB3, EPHB1, EPHB4 ERBB3, TGFBR1

*Genes with common alternative names are in parentheses, and those related to the PI3K, MEK, or PDGFR pathways are in bold